Skip to main content
. 2017 Mar 29;12(3):323–332. doi: 10.1007/s11523-017-0482-9

Fig. 2.

Fig. 2

Plasma concentration-time profiles of BEZ235 and everolimus. a) Plasma concentration-time profile of BEZ235 on day 1 after 200, 400, and 800 mg/day dose. b) Plasma concentration-time profile of everolimus on day 1 and day 28 after 2.5 mg/day dose